Affimed prices public offering to finance...Following phantastic AFM13 data at AACR, Affimed N.V. prices it public offering at $84.4m. more ➔
GeNeuro finds biologic against post-COVID... Swiss neurology specialist GeNeuro SA present first data linking silent COVID-19-induced inflammations to neuropsyciatric diseases. more ➔
Catalent swallows VMIC LtdCatalent has acquired a biologics manufacturing site from VMIC Ltd that is still under construction. more ➔
AXA launches €440 m private equity healt...AXA IM Alts, has launched a Global Health Strategy following a €18m cornerstone commitment from AXA Group, as it builds on its existing offering in the sector. more ➔
Bayer Leaps to invests €1.3bn externallyGerman Bayer AG has announced it will channel at least €1.3b by the end of 2024 in its investment arm ‘Leaps by Bayer’. more ➔
Avantium closes financing for FDCA plantAvantium NV has reached financial close for the construction of a 5,000 ton FDCA plant, one of the two monomers needed to make fossil-free, recyclable PEF. more ➔
Novo Holdings co-leads €40m Qure.ai fina...Deep learning medical imaging specialist Qure.ai raises $40m from healthcare investors Novo Holdings and HealthQuad more ➔
Sanofi and IGM Biosciences Inc. in $6.15bn...Sanofi and IGM Biosciences have entered into a broad antibody discovery collaboration that could bring in IGM $6bn if all milestones are met. more ➔
XNK Therapeutics AB raises €12.75mXNK Therapeutics AB has secured a private placement of €12.75m led by Flerie Invest AB to finance Phase II development of CellProtect + Isatuximab in multiple myeloma. more ➔
CSL Behring files for MAA of haemophilia B...CSL Behring has filed for accelerated approval of the first hemophilia B gene therapy in Europe. more ➔
